Join the club for FREE to access the whole archive and other member benefits.

Bioage's lead therapies moved closer to the clinic

Lead therapies of BioAge to treat age related diseases enter phase 2 trials


Key points from article :

BioAge after raising series c funding round, moved its lead therapies, BGE-117 and BGE-175, into phase 2 clinical trials.

BGE-175, will treat immune aging in older patients - initially those hospitalized with COVID-19.

“These additional funds... reverse or eradicate diseases and extend healthspan,” Kristen Fortney, CEO and co-founder, BioAge.

The new round brings the total amount of venture capital funding raised by BioAge to $127 million.

"Investors are showing more and more enthusiasm for aging as a space" - Fortney.

BioAge also announced the appointment of veteran biopharmaceutical drug developer Paul Rubin, as its chief medical officer.

Drugs are ready to begin phase 2 trials in indications that presently have no good therapeutic options.

“Our drugs can address age-related deficiencies in acute conditions, chronic diseases, resulting in healthy aging.” -Dr Rubin.

Mentioned in this article:

Click on resource name for more details.


Developing a broad pipeline of therapies to extend human healthspan and lifespan

Kristen Fortney

Chief Executive Officer and co-founder at BioAge

Paul Rubin

Chief Medical Officer at Bioage Labs and Pharma and biotech Consultant at Rubin Pharma

Topics mentioned on this page:
Investments, Immunosenescence